Nurix Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Nurix TherapeuticsDer Gewinn des Unternehmens wird voraussichtlich um 3.6% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 23.7% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 2.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -106.4% betragen.

Wichtige Informationen

-3.1%

Wachstumsrate der Gewinne

3.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.2%
Wachstumsrate der Einnahmen	24.1%
Zukünftige Eigenkapitalrendite	-106.4%
Analystenabdeckung	Good
Zuletzt aktualisiert	26 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Jun 19

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

May 29

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Apr 15

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Apr 14

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Feb 20

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Jan 16

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Dec 29

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Oct 14

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Oct 13

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Sep 30

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

Apr 18

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Apr 15

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Nov 28

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Oct 06

Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M

Jul 07

FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.

Jun 30

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Jun 21

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:NRIX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
11/30/2026	76	-254	-230	-222	8
11/30/2025	67	-213	-203	-179	11
11/30/2024	72	-172	-169	-147	11
2/29/2024	81	-145	-84	-75	N/A
11/30/2023	77	-144	-90	-81	N/A
8/31/2023	69	-149	-154	-146	N/A
5/31/2023	61	-157	-161	-151	N/A
2/28/2023	42	-179	-177	-166	N/A
11/30/2022	39	-180	-172	-160	N/A
8/31/2022	39	-171	-163	-153	N/A
5/31/2022	39	-154	-145	-136	N/A
2/28/2022	34	-135	-143	-135	N/A
11/30/2021	30	-117	-90	-84	N/A
8/31/2021	29	-99	-80	-74	N/A
5/31/2021	23	-89	-56	-50	N/A
2/28/2021	20	-63	-38	-33	N/A
11/30/2020	18	-43	-5	0	N/A
8/31/2020	13	-37	3	8	N/A
5/31/2020	19	-21	47	50	N/A
2/29/2020	25	-24	49	51	N/A
11/30/2019	31	-22	-1	1	N/A
11/30/2018	37	-9	-33	-32	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: NRIX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: NRIX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: NRIX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: NRIXDie Einnahmen des Unternehmens (23.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: NRIXDie Einnahmen des Unternehmens (23.7% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: NRIX wird voraussichtlich in 3 Jahren unrentabel sein.

Nurix Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 9.4% to US$24.09

Consensus revenue estimates increase by 21%

Consensus revenue estimates increase by 39%

Consensus revenue estimates decrease by 23%, EPS upgraded

Price target decreased by 7.7% to US$31.45

Price target decreased to US$34.91

Recent updates

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia At the European Hematology Association Congress

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

Nurix Therapeutics, Inc. Appoints Paula G. O’Connor as Chief Medical Officer and Pasit Phiasivongsa as Chief Technical Officer

Nurix Therapeutics Announces Board Chair Transition

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Nurix Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics, Inc. Reports First Clinical Evidence of CNS Activity of NX-5948, A Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

Nurix Therapeutics, Inc., Annual General Meeting, May 20, 2024

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on Nx-2127 Phase 1 Trial

Price target decreased by 9.4% to US$24.09

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Chief Financial Officer notifies of intention to sell stock

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

Nurix Therapeutics, Inc. Announces Publication in the Journal Science Identifying A New Class of Btk Mutations That Are Susceptible to Nx-2127, A Novel Btk and Ikzf1/3 Degrader

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Chief Financial Officer notifies of intention to sell stock

Nurix Therapeutics, Inc. Presents Positive Clinical Data from its Novel Bruton's Tyrosine Kinase (BTK) Degrader Programs, Nx-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics, Inc. Announces Partial Clinical Hold for Nx-2127 Phase 1 Trial

New minor risk - Share price stability

Consensus revenue estimates increase by 21%

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Third quarter 2023 earnings: EPS exceeds analyst expectations

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics, Inc. Plans to Initiate Two New Phase 1b Dose Expansion Cohorts in Ongoing Phase 1a/1b Clinical Trial of NX-2127 in Patients with Relapsed or Refractory B-Cell Malignancies

Consensus revenue estimates increase by 39%

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates decrease by 23%, EPS upgraded

Price target decreased by 7.7% to US$31.45

Full year 2022 earnings: EPS and revenues miss analyst expectations

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Price target decreased to US$34.91

Nurix Announces Initial Nx-1607 Phase 1 Data Presented At the 37Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc) Demonstrating Targeted Cbl-B Inhibition in Patients with Advanced Malignancies

Nurix Therapeutics Inc. Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation Summit

Price target decreased to US$34.91

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Nurix Therapeutics, Inc. Appoints Edward C. Saltzman to its Board of Directors

Nurix Therapeutics, Inc. Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer

Price target decreased to US$38.20

Price target decreased to US$38.80

Nurix Therapeutics, Inc. has announced a Derivatives Offering in the amount of $54.996046 million.

Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M

Nurix Therapeutics, Inc. Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.

Nurix Therapeutics, Inc.(NasdaqGM:NRIX) dropped from Russell 2000 Growth Index

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs At the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Chief Financial Officer exercised options to buy US$621k worth of stock.

Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development

Nurix Therapeutics, Inc. Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948

High number of new directors

Nurix Therapeutics, Inc. Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Nurix Therapeutics, Inc Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors

Nurix Therapeutics Receives Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607

Nurix Therapeutics, Inc. Announces Resignation of Jeffrey K. Tong as Class II Member of the Board and as a Member of the Board's Audit Committee and Compensation Committee

We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth

Price target decreased to US$47.33